학술논문
Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15698041